Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Receivables - NetShares IssuedShort-Term Debt repayments
Ratios

HeartSciences (HSCS) EBIAT (2021 - 2026)

HeartSciences' EBIAT history spans 6 years, with the latest figure at -$2.0 million for Q1 2026.

  • For Q1 2026, EBIAT rose 21.73% year-over-year to -$2.0 million; the TTM value through Jan 2026 reached -$8.5 million, changed 0.37%, while the annual FY2025 figure was -$8.8 million, 32.7% down from the prior year.
  • EBIAT reached -$2.0 million in Q1 2026 per HSCS's latest filing, up from -$2.4 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$1.2 million in Q1 2022 to a low of -$2.5 million in Q1 2025.
  • Average EBIAT over 5 years is -$1.8 million, with a median of -$1.8 million recorded in 2024.
  • Peak YoY movement for EBIAT: tumbled 213.5% in 2022, then rose 21.73% in 2026.
  • A 5-year view of EBIAT shows it stood at -$1.8 million in 2022, then increased by 3.22% to -$1.7 million in 2023, then dropped by 19.13% to -$2.1 million in 2024, then dropped by 12.86% to -$2.4 million in 2025, then increased by 15.55% to -$2.0 million in 2026.
  • Per Business Quant, the three most recent readings for HSCS's EBIAT are -$2.0 million (Q1 2026), -$2.4 million (Q4 2025), and -$2.1 million (Q3 2025).